JP4738346B2 - GlycoPEG化された第IX因子 - Google Patents
GlycoPEG化された第IX因子 Download PDFInfo
- Publication number
- JP4738346B2 JP4738346B2 JP2006542888A JP2006542888A JP4738346B2 JP 4738346 B2 JP4738346 B2 JP 4738346B2 JP 2006542888 A JP2006542888 A JP 2006542888A JP 2006542888 A JP2006542888 A JP 2006542888A JP 4738346 B2 JP4738346 B2 JP 4738346B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- factor
- peg
- moiety
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 COC(*)(CC1O)OC(C(C(C*)O)O)C1N* Chemical compound COC(*)(CC1O)OC(C(C(C*)O)O)C1N* 0.000 description 4
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52708903P | 2003-12-03 | 2003-12-03 | |
US60/527,089 | 2003-12-03 | ||
US53938704P | 2004-01-26 | 2004-01-26 | |
US60/539,387 | 2004-01-26 | ||
US59274404P | 2004-07-29 | 2004-07-29 | |
US60/592,744 | 2004-07-29 | ||
US61451804P | 2004-09-29 | 2004-09-29 | |
US60/614,518 | 2004-09-29 | ||
US62338704P | 2004-10-29 | 2004-10-29 | |
US60/623,387 | 2004-10-29 | ||
PCT/US2004/041070 WO2005055950A2 (en) | 2003-12-03 | 2004-12-03 | Glycopegylated factor ix |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007513190A JP2007513190A (ja) | 2007-05-24 |
JP2007513190A5 JP2007513190A5 (de) | 2008-08-28 |
JP4738346B2 true JP4738346B2 (ja) | 2011-08-03 |
Family
ID=34682416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006542888A Expired - Fee Related JP4738346B2 (ja) | 2003-12-03 | 2004-12-03 | GlycoPEG化された第IX因子 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1694315A4 (de) |
JP (1) | JP4738346B2 (de) |
KR (1) | KR101209111B1 (de) |
AU (1) | AU2004296860B2 (de) |
BR (1) | BRPI0417341A (de) |
CA (1) | CA2549413A1 (de) |
IL (1) | IL175661A0 (de) |
MX (1) | MXPA06006023A (de) |
NZ (1) | NZ546733A (de) |
WO (1) | WO2005055950A2 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
WO2004099231A2 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
BRPI0408358A (pt) | 2003-03-14 | 2006-03-21 | Neose Technologies Inc | polìmeros hidrossolúveis ramificados e seus conjugados |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
CA2552892C (en) | 2004-01-08 | 2014-08-05 | Neose Technologies, Inc. | O-linked glycosylation of peptides |
AU2014280936B2 (en) * | 2004-06-30 | 2016-12-15 | Nektar Therapeutics | Polymer-factor ix moiety conjugates |
JP2008505119A (ja) | 2004-06-30 | 2008-02-21 | ネクター セラピューティクス アラバマ,コーポレイション | 高分子−第ix因子部分の抱合体 |
WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
EP1814573B1 (de) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf) |
ES2449195T3 (es) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Factor estimulante de colonias de granulocitos glicopegilado |
EP1871795A4 (de) | 2005-04-08 | 2010-03-31 | Biogenerix Ag | Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons |
US20080255026A1 (en) | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
AU2006280932A1 (en) * | 2005-08-19 | 2007-02-22 | Novo Nordisk A/S | Glycopegylated factor VII and factor Vila |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
WO2008057683A2 (en) | 2006-10-03 | 2008-05-15 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
DK2068907T3 (en) * | 2006-10-04 | 2018-01-15 | Novo Nordisk As | GLYCEROL BOND PEGYLED SUGAR AND GLYCOPE Peptides |
EP2101821B1 (de) | 2006-12-15 | 2014-08-13 | Baxter International Inc. | Faktor-viia-(poly)sialsäurekonjugat mit verlängerter in-vivo-halbwertszeit |
KR20100016160A (ko) | 2007-04-03 | 2010-02-12 | 바이오제너릭스 에이지 | 글리코페길화 g―csf를 이용하는 치료 방법 |
JP6050927B2 (ja) * | 2007-04-26 | 2016-12-21 | シーエヌジェイ ホールディングス,インコーポレイテッド | 高シアル酸含量を有する組換えビタミンk依存性タンパク質およびその調製方法 |
WO2008154639A2 (en) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Improved process for the production of nucleotide sugars |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
CN102026653B (zh) * | 2007-10-15 | 2014-06-18 | 北卡罗来纳-查佩尔山大学 | 半衰期延长的人因子ⅸ变体 |
NZ585835A (en) * | 2007-12-27 | 2012-07-27 | Baxter Int | Chemically modified factor IX comprising a hydrophilic polymer attached via a releasable linker |
ES2476690T3 (es) | 2008-02-27 | 2014-07-15 | Novo Nordisk A/S | Moléculas conjugadas del Factor VIII |
WO2009137254A2 (en) * | 2008-04-16 | 2009-11-12 | Bayer Healthcare Llc | Modified factor ix polypeptides and uses thereof |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
NZ597600A (en) | 2009-07-27 | 2014-05-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
SG10201401194VA (en) | 2009-07-27 | 2014-07-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
EP2459224B1 (de) | 2009-07-27 | 2016-06-01 | Baxalta GmbH | Koagulationsproteinkonjugate |
US20120164130A1 (en) * | 2009-07-31 | 2012-06-28 | Bayer Healthcare Llc | Modified Factor IX Polypeptides and Uses Thereof |
US8697844B2 (en) | 2009-11-24 | 2014-04-15 | Novo Nordisk A/S | Method of purifying pegylated proteins |
MX356527B (es) | 2010-07-09 | 2018-06-01 | Bioverativ Therapeutics Inc | Polipeptidos de factor ix y metodos para usarlos. |
NZ612320A (en) | 2010-12-22 | 2015-06-26 | Baxter Healthcare Sa | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
TW201519900A (zh) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法 |
BR112021017062A2 (pt) | 2019-03-19 | 2021-11-16 | CSL Behring Lengnau AG | Variantes do fator ix e usos das mesmas em terapia |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59172425A (ja) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
AU744303B2 (en) * | 1997-12-01 | 2002-02-21 | Neose Technologies, Inc. | Enzymatic synthesis of gangliosides |
EP2279755B1 (de) * | 2001-10-10 | 2014-02-26 | ratiopharm GmbH | Neumodulierung und Glykokonjugation von Fibroblasten-Wachstumsfaktor (FGF) |
-
2004
- 2004-12-03 WO PCT/US2004/041070 patent/WO2005055950A2/en active Application Filing
- 2004-12-03 NZ NZ546733A patent/NZ546733A/en not_active IP Right Cessation
- 2004-12-03 BR BRPI0417341-4A patent/BRPI0417341A/pt not_active Application Discontinuation
- 2004-12-03 JP JP2006542888A patent/JP4738346B2/ja not_active Expired - Fee Related
- 2004-12-03 AU AU2004296860A patent/AU2004296860B2/en not_active Ceased
- 2004-12-03 CA CA002549413A patent/CA2549413A1/en not_active Abandoned
- 2004-12-03 EP EP04813394A patent/EP1694315A4/de not_active Withdrawn
- 2004-12-03 MX MXPA06006023A patent/MXPA06006023A/es active IP Right Grant
-
2006
- 2006-05-16 IL IL175661A patent/IL175661A0/en unknown
- 2006-05-30 KR KR1020067010603A patent/KR101209111B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MXPA06006023A (es) | 2006-08-23 |
EP1694315A4 (de) | 2009-10-28 |
AU2004296860A1 (en) | 2005-06-23 |
WO2005055950A3 (en) | 2005-10-20 |
AU2004296860B2 (en) | 2010-04-22 |
KR101209111B1 (ko) | 2012-12-06 |
BRPI0417341A (pt) | 2007-04-17 |
KR20060123224A (ko) | 2006-12-01 |
CA2549413A1 (en) | 2005-06-23 |
NZ546733A (en) | 2009-07-31 |
IL175661A0 (en) | 2006-09-05 |
JP2007513190A (ja) | 2007-05-24 |
EP1694315A2 (de) | 2006-08-30 |
WO2005055950A2 (en) | 2005-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4738346B2 (ja) | GlycoPEG化された第IX因子 | |
JP4657219B2 (ja) | GlycoPEG化された顆粒球コロニー刺激因子 | |
JP5922065B2 (ja) | グリコpeg化g−csfを用いた治療方法 | |
JP4719686B2 (ja) | GlycoPEG化エリスロポエチン | |
JP5216580B2 (ja) | グリコペグ化第ix因子 | |
JP4951527B2 (ja) | 糖peg化顆粒球コロニー刺激因子 | |
US8911967B2 (en) | One pot desialylation and glycopegylation of therapeutic peptides | |
US8632770B2 (en) | Glycopegylated factor IX | |
US20080318850A1 (en) | Glycopegylated Factor Ix | |
JP2007515410A (ja) | GlycoPEG化卵胞刺激ホルモン | |
JP2009515508A (ja) | グリコpeg化因子viiおよび因子viia | |
ZA200604554B (en) | Glycopegylated Factor IX | |
RU2400490C2 (ru) | Гликопэгилированный гранулоцитарный колониестимулирующий фактор | |
JP2008542288A (ja) | グリコpeg化エリスロポエチン製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071010 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080711 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100715 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100812 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100819 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110112 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110329 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110426 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140513 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |